Spotlight on Lanreotide Autogel® in Acromegaly

被引：0
|
作者：
Jamie D. Croxtall
Lesley J. Scott
机构：
[1] Wolters Kluwer Health ¦ Adis,
[2] Wolters Kluwer Health,undefined
来源：
BioDrugs | 2008年 / 22卷
关键词：
Growth Hormone; Acromegaly; Growth Hormone Level; Lanreotide; Somatuline;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Lanreotide Autogel® (ATG) [Somatuline® Depot]1 is a novel, long-acting preparation of the somatostatin analog lanreotide acetate that acts via somatostatin receptors to reduce both growth hormone (GH) and insulin-like growth factor-I (IGF-I) levels. It is indicated for the management of acromegaly and, relative to most other licensed agents, it has a favorable pharmacokinetic profile that permits administration once every 28–42 days.
引用
收藏
页码：275 / 277
页数：2
相关论文
共 50 条
  • [41] Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide
    M. Suliman
    R. Jenkins
    R. Ross
    T. Powell
    R. Battersby
    D. R. Cullen
    Journal of Endocrinological Investigation, 1999, 22 : 409 - 418
  • [42] Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide
    Suliman, M
    Jenkins, R
    Ross, R
    Powell, T
    Battersby, R
    Cullen, DR
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1999, 22 (06) : 409 - 418
  • [43] Glucose status in patients with acromegaly receiving primary treatment with the somatostatin analog lanreotide
    Couture, Elisabeth
    Bongard, Vanina
    Maiza, Jean-Christophe
    Bennet, Antoine
    Caron, Philippe
    PITUITARY, 2012, 15 (04) : 518 - 525
  • [44] Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly
    Colao, Annamaria
    Auriemma, Renata S.
    Rebora, Alberto
    Galdiero, Mariano
    Resmini, Eugenia
    Minuto, Francesco
    Lombardi, Gaetano
    Pivonello, Rosario
    Ferone, Diego
    CLINICAL ENDOCRINOLOGY, 2009, 71 (02) : 237 - 245
  • [45] Biochemical efficacy of long-acting lanreotide depot/Autogel in patients with acromegaly naïve to somatostatin-receptor ligands: analysis of three multicenter clinical trials
    Hussain Alquraini
    Maria del Pilar Schneider
    Beloo Mirakhur
    Ariel Barkan
    Pituitary, 2018, 21 : 283 - 289
  • [46] Tamoxifen enhances the control of acromegaly treated with somatostatin analog lanreotide
    Jean-Christophe Maiza
    Stéphane Castillo-Ros
    Maria Matta
    Antoine Bennet
    Philippe Caron
    Pituitary, 2012, 15 (Suppl 1) : S23 - S27
  • [47] Efficacy of long-term lanreotide treatment in patients with acromegaly
    Toledano, Yoel
    Rot, Liat
    Greenman, Yona
    Orlovsky, Sophia
    Pauker, Yulia
    Olchovsky, David
    Eliash, Achia
    Bardicef, Orit
    Makhoul, Ofa
    Tsvetov, Gloria
    Gershinsky, Michal
    Cohen-Ouaqnine, Odile
    Ness-Abramof, Rosane
    Adnan, Zaina
    Ilany, Jacob
    Guttmann, Hadassah
    Sapir, Mazal
    Benbassat, Carlos
    Shimon, Ilan
    PITUITARY, 2009, 12 (04) : 285 - 293
  • [48] Lanreotide autogel and insulin sensitivity markers: Report of 5 acromegalic patients and literature review
    Ertorer, Melek Eda
    Bakiner, Okan
    Anaforoglu, Inan
    Bozkirli, Emre
    Tutuncu, Neslihan Bascil
    Demirag, Nigun Guvener
    NEUROENDOCRINOLOGY LETTERS, 2007, 28 (06) : 727 - 733
  • [49] Efficacy of long-term lanreotide treatment in patients with acromegaly
    Yoel Toledano
    Liat Rot
    Yona Greenman
    Sophia Orlovsky
    Yulia Pauker
    David Olchovsky
    Achia Eliash
    Orit Bardicef
    Ofa Makhoul
    Gloria Tsvetov
    Michal Gershinsky
    Odile Cohen-Ouaqnine
    Rosane Ness-Abramof
    Zaina Adnan
    Jacob Ilany
    Hadassah Guttmann
    Mazal Sapir
    Carlos Benbassat
    Ilan Shimon
    Pituitary, 2009, 12 : 285 - 293
  • [50] A multicenter, observational study of lanreotide depot/autogel (LAN) in patients with acromegaly in the United States: 2-year experience from the SODA registry
    Salvatori, Roberto
    Gordon, Murray B.
    Woodmansee, Whitney W.
    Ioachimescu, Adriana G.
    Carver, Don W.
    Mirakhur, Beloo
    Cox, David
    Molitch, Mark E.
    PITUITARY, 2017, 20 (06) : 605 - 618
12345